GeneDx Holdings (WGS) Common Equity (2020 - 2026)

GeneDx Holdings (WGS) has reported Common Equity for 7 consecutive years, with $244.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 11.88% year-over-year to $244.2 million in Q2 2026; TTM through Jun 2026 was $244.2 million, a 11.88% decrease from a year earlier, with the FY2025 full-year figure at $308.2 million, up 25.66% from the prior year.
• Common Equity was $244.2 million for Q2 2026 at GeneDx Holdings, down from $254.1 million in the prior quarter.
• Over five years, Common Equity peaked at $637.3 million in Q2 2022 and troughed at $194.0 million in Q2 2024.
• A 5-year average of $298.5 million and a median of $255.8 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 212.49% in 2022 and plunged 54.7% in 2023, its largest moves.
• Over 5 years, Common Equity stood at $253.7 million in 2022, then dropped by 10.13% to $228.0 million in 2023, then rose by 7.56% to $245.2 million in 2024, then grew by 25.66% to $308.2 million in 2025, then declined by 20.75% to $244.2 million in 2026.
• The last three Common Equity figures came in at $244.2 million (Q2 2026), $254.1 million (Q1 2026), and $308.2 million (Q4 2025), per Business Quant data.